Telix Pharmaceuticals Limited Net Income
| TLX Stock | 7.10 0.14 2.01% |
As of the 8th of February, Telix Pharmaceuticals has the Coefficient Of Variation of (544.04), variance of 8.43, and Risk Adjusted Performance of (0.14). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Telix Pharmaceuticals, as well as the relationship between them.
Telix Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.906 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 44.9 M | 47.2 M | |
| Net Income From Continuing Ops | 57.4 M | 60.3 M | |
| Net Income Per Share | 0.17 | 0.18 | |
| Net Income Per E B T | 0.80 | 0.77 |
Telix | Net Income | Build AI portfolio with Telix Stock |
The evolution of Net Income for Telix Pharmaceuticals Limited provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Telix Pharmaceuticals compares to historical norms and industry peers.
Latest Telix Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Telix Pharmaceuticals Limited over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Telix Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Telix Pharmaceuticals Limited operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Telix Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 49.92 M | 10 Years Trend |
|
Net Income |
| Timeline |
Telix Net Income Regression Statistics
| Arithmetic Mean | (7,817,927) | |
| Geometric Mean | 6,544,980 | |
| Coefficient Of Variation | (516.72) | |
| Mean Deviation | 27,303,905 | |
| Median | (2,505,057) | |
| Standard Deviation | 40,396,546 | |
| Sample Variance | 1631.9T | |
| Range | 154M | |
| R-Value | 0.08 | |
| Mean Square Error | 1728.3T | |
| R-Squared | 0.01 | |
| Significance | 0.75 | |
| Slope | 673,434 | |
| Total Sum of Squares | 26110.1T |
Telix Net Income History
Other Fundumenentals of Telix Pharmaceuticals
Telix Pharmaceuticals Net Income component correlations
Telix Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Telix Pharmaceuticals is extremely important. It helps to project a fair market value of Telix Stock properly, considering its historical fundamentals such as Net Income. Since Telix Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Telix Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Telix Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telix Pharmaceuticals. If investors know Telix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Telix Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.02 | Revenue Per Share | Quarterly Revenue Growth 0.589 | Return On Assets | Return On Equity |
The market value of Telix Pharmaceuticals is measured differently than its book value, which is the value of Telix that is recorded on the company's balance sheet. Investors also form their own opinion of Telix Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Telix Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telix Pharmaceuticals' market value can be influenced by many factors that don't directly affect Telix Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Telix Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Telix Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Telix Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Telix Pharmaceuticals.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Telix Pharmaceuticals on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Telix Pharmaceuticals Limited or generate 0.0% return on investment in Telix Pharmaceuticals over 90 days. Telix Pharmaceuticals is related to or competes with Mirum Pharmaceuticals, Soleno Therapeutics, Dyne Therapeutics, ADMA Biologics, Belite Bio, Ligand Pharmaceuticals, and ACADIA Pharmaceuticals. Telix Pharmaceuticals is entity of United States More
Telix Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Telix Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Telix Pharmaceuticals Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 15.35 | |||
| Value At Risk | (5.43) | |||
| Potential Upside | 4.24 |
Telix Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telix Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Telix Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Telix Pharmaceuticals historical prices to predict the future Telix Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (0.54) |
Telix Pharmaceuticals February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 2.25 | |||
| Coefficient Of Variation | (544.04) | |||
| Standard Deviation | 2.9 | |||
| Variance | 8.43 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 15.35 | |||
| Value At Risk | (5.43) | |||
| Potential Upside | 4.24 | |||
| Skewness | 0.4833 | |||
| Kurtosis | 0.8761 |
Telix Pharmaceuticals Backtested Returns
Telix Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.18, which indicates the firm had a -0.18 % return per unit of risk over the last 3 months. Telix Pharmaceuticals Limited exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Telix Pharmaceuticals' Variance of 8.43, coefficient of variation of (544.04), and Risk Adjusted Performance of (0.14) to confirm the risk estimate we provide. The entity has a beta of 1.0, which indicates a somewhat significant risk relative to the market. Telix Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Telix Pharmaceuticals is expected to follow. At this point, Telix Pharmaceuticals has a negative expected return of -0.52%. Please make sure to validate Telix Pharmaceuticals' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Telix Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.75 |
Good predictability
Telix Pharmaceuticals Limited has good predictability. Overlapping area represents the amount of predictability between Telix Pharmaceuticals time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Telix Pharmaceuticals price movement. The serial correlation of 0.75 indicates that around 75.0% of current Telix Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.75 | |
| Spearman Rank Test | 0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Telix Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Telix Pharmaceuticals Limited reported net income of 49.92 M. This is 85.37% lower than that of the Healthcare sector and 28.73% lower than that of the Biotechnology industry. The net income for all United States stocks is 91.26% higher than that of the company.
Telix Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telix Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Telix Pharmaceuticals by comparing valuation metrics of similar companies.Telix Pharmaceuticals is currently under evaluation in net income category among its peers.
Telix Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Telix Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Telix Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Telix Fundamentals
| Return On Equity | 0.0314 | ||||
| Return On Asset | 0.0208 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 2.52 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Shares Owned By Institutions | 0.14 % | ||||
| Number Of Shares Shorted | 176.46 K | ||||
| Price To Book | 5.62 X | ||||
| Price To Sales | 3.58 X | ||||
| Revenue | 783.21 M | ||||
| Gross Profit | 358.28 M | ||||
| EBITDA | 98.23 M | ||||
| Net Income | 49.92 M | ||||
| Total Debt | 581.45 M | ||||
| Book Value Per Share | 1.25 X | ||||
| Cash Flow From Operations | 43.03 M | ||||
| Short Ratio | 1.12 X | ||||
| Earnings Per Share | 0.02 X | ||||
| Target Price | 20.9 | ||||
| Beta | 1.22 | ||||
| Market Capitalization | 3.28 B | ||||
| Total Asset | 1.52 B | ||||
| Retained Earnings | (212.96 M) | ||||
| Working Capital | 587.65 M | ||||
| Net Asset | 1.52 B |
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.